STAT+: At JPM, biotech’s most prolific dealmaker sees a rosy 2024 for acquisitions

Eric Tokat, biotech’s most prolific dealmaker, believes 2024 will be another strong year for acquisitions in the industry. #JPM24
Click here to view original post

Advertisement — Advertise with Biotech Networks